Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
May act as a receptor in regulating T-cell proliferation.. Additionally we are shipping CD5 Proteins (20) and CD5 Kits (16) and many more products for this protein.
Showing 10 out of 1299 products:
Human Monoclonal CD5 Primary Antibody for IHC (p) - ABIN1687421
Galgani, Insabato, Calì, Della Gatta, Mirra, Papaccio, Santopaolo, Alviggi, Mollo, Strina, Matarese, Beguinot, De Placido, Ulianich: Regulatory T cells, inflammation, and endoplasmic reticulum stress in women with defective endometrial receptivity. in Fertility and sterility 2015
Show all 21 references for 1687421
Rat (Rattus) Monoclonal CD5 Primary Antibody for FACS, IHC (fro) - ABIN120388
Dallman, Thomas, Green: MRC OX-19: a monoclonal antibody that labels rat T lymphocytes and augments in vitro proliferative responses. in European journal of immunology 1984
Show all 4 references for 120388
Rat (Rattus) Monoclonal CD5 Primary Antibody for FACS - ABIN120386
Barclay: The localization of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues. in Immunology 1981
Show all 3 references for 120386
Human Monoclonal CD5 Primary Antibody for FACS - ABIN951342
Raman, Kuo, Deshane, Litchfield, Kimberly: Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5. in The Journal of biological chemistry 1998
Show all 3 references for 951342
Human Monoclonal CD5 Primary Antibody for IHC (fro), IHC (p) - ABIN114633
Kasaian, Ikematsu, Casali: CD5+ B lymphocytes. in Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1991
Show all 2 references for 114633
Human Monoclonal CD5 Primary Antibody for FACS, IHC (p) - ABIN1106434
Wang, Kvalheim, Kvaløy, Beiske, Jakobsen, Wijdenes, Pihl, Fodstad: An effective immunomagnetic method for bone marrow purging in T cell malignancies. in Bone marrow transplantation 1992
Human Monoclonal CD5 Primary Antibody for FACS - ABIN1106444
Garnache-Ottou, Chaperot, Biichle, Ferrand, Remy-Martin, Deconinck, de Tailly, Bulabois, Poulet, Kuhlein, Jacob, Salaun, Arock, Drenou, Schillinger, Seilles, Tiberghien, Bensa, Plumas, Saas: Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. in Blood 2005
Mouse (Murine) Monoclonal CD5 Primary Antibody for FACS - ABIN120102
Cobbold, Jayasuriya, Nash, Prospero, Waldmann: Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. in Nature 1985
Human Polyclonal CD5 Primary Antibody for WB - ABIN2774224
Garza-Garcia, Esposito, Rieping, Harris, Briggs, Brown, Driscoll: Three-dimensional solution structure and conformational plasticity of the N-terminal scavenger receptor cysteine-rich domain of human CD5. in Journal of molecular biology 2008
CD5-CK2 signaling axis regulates positive selection by modulating activation of ERK and promoting survival independent of proximal TCR signals
the reduction in the positive selection conferred by CD5 overexpression was unaffected by SHP-1 deficiency.
In mice lacking functional KDELR1, surviving naive T cells expressed significantly higher levels of CD5, a surrogate marker of TCR self-reactivity.
In mouse tumor models, CD5(+) but not CD5(-) B cells promoted tumor growth. The results demonstrate a critical role of CD5(+) B cells in promoting cancer.
CD5 and CD72 (show CD72 Antibodies) play a critical role in maintaining regulatory T and B cell homeostasis
CD5 promoted Treg cell induction in response to self and tolerizing antigens by blocking mTOR (show FRAP1 Antibodies) activation.
Data indicate that CD5-casein kinase 2 (CK2 (show CSNK2A1 Antibodies)) signaling is necessary for efficient nuclear localization of orphan nuclear receptor (show NR1D1 Antibodies) ROR (show RORB Antibodies)-gammaT (RORgammat).
These results support the notion that the distal cytoplasmic domain of CD5, including Y463, plays a relevant role in the downmodulation of TCR signals in thymocytes via c-Cbl (show CBL Antibodies).
Although the percentage of CD1d (show CD1D Antibodies)(hi)CD5+ subset in splenic B cells does not change significantly, percent IL-10 (show IL10 Antibodies)-expressing cells among total splenic B cells or the CD1dhiCD5+ population significantly increases 3-7 days after rCRT/39-272 administration
Different CD5 expression levels influence the proliferation dynamics of activated naive CD4 (show CD4 Antibodies)+ T cells while leaving the conversion rate of those cells into memory cells unaffected.
CD5 transcription is increased, leading to the production of three mRNA isoforms by APA (show ENPEP Antibodies), all contributing for protein production, at different levels. PTBP1 (show PTBP1 Antibodies) binds in the vicinity of pA1 (show PAGR1 Antibodies), leading to an increase in mRNA levels and miR (show MLXIP Antibodies)-204 targets the longer CD5 mRNA.
High CD5 expression is associated with lymphoma in Waldeyer ring.
Thus, trans-signaling of IL-6 (show IL6 Antibodies) can only occur via sIL (show PMEL Antibodies)-6R, but not sCD5 (show SCD5 Antibodies).
The major proportion of CD5(low) B cells in patients are leukemic, thus identifying CD5(low) B cells as an important component of CLL, with implications for CLL pathogenesis, clinical monitoring, and the development of anti-CD5-directed therapies.
the CD5 Pro224-Ala471 haplotype in homozygosis improved melanoma survival in the entire set of patients (HR = 0.27, 95% CI 0.11-0.67, Adj. p = 0.005). These findings highlight the relevance of genetic variability in immune-related genes for clinical outcome in melanoma.
R-EPOCH therapy does not seem to impact the known poorer prognosis of patients with de novo CD5+ diffuse large B-cell lymphoma , and CD5 expression was still an independent prognostic factor in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
CD5+B lymphocytes were increased and activated in autoimmune hemolytic anemia patients.
This study confirms the poor prognosis of de novo CD5+ DLBCL in a large multi-center cohort despite initial rituximab-containing chemotherapy and suggests that stem cell transplantation fails to salvage the majority of these patients.
5.2 % were positive for CD5 and 5.7 % positive for epstein-Barr virus encoded RNA
CD5 polymorphisms are associated with systemic lupus erythematosus.
Findings suggest that development, selection and function of different B- and T-cell subsets may be directly or indirectly dependent on different glycan structures associated with CD5 or CD5-like (show CD5L Antibodies) molecules expressed on T cells compared to B (show TDO2 Antibodies) cells.
May act as a receptor in regulating T-cell proliferation.
, t-cell surface glycoprotein CD5-like
, T-cell surface glycoprotein CD5
, lymphocyte antigen 1
, CD5 antigen (p56-62)
, lymphocyte antigen T1/Leu-1
, CD5 antigen
, Lymphocyte antigen CD5
, CD74 antigen, invariant polypeptide of major
, lymphocyte receptor CD5